[{"orgOrder":0,"company":"Mabpharm","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"ACE-MAB","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mabpharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabpharm \/ Sorrento Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Mabpharm \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qingfeng Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Qingfeng Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Changsha King-eagle Med Technology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Changsha King-eagle Med Technology","highestDevelopmentStatusID":"1","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Changsha King-eagle Med Technology"},{"orgOrder":0,"company":"Kawin Technology","sponsor":"KawinGreen Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Sofosbuvir","moa":"Hepatitis C virus NS5B RNA-dependent RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kawin Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kawin Technology \/ KawinGreen Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Kawin Technology \/ KawinGreen Biotech"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lopinavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qingfeng Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Qingfeng Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sihuan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sihuan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai BDgene","sponsor":"Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BD111","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Shanghai BDgene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai BDgene \/ Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai BDgene \/ Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran"},{"orgOrder":0,"company":"BravoVax","sponsor":"GeoVax Labs","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"2019-nCoV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BravoVax","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BravoVax \/ GeoVax Labs","highestDevelopmentStatusID":"1","companyTruncated":"BravoVax \/ GeoVax Labs"},{"orgOrder":0,"company":"AIM Vaccine","sponsor":"Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"COVID-19 Omicron BA.5 mRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AIM Vaccine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","highestDevelopmentStatusID":"1","companyTruncated":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SA58","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sinovac Biotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sinovac Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Beijing Ditan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SA58","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sinovac Biotech \/ Beijing Ditan Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Sinovac Biotech \/ Beijing Ditan Hospital"},{"orgOrder":0,"company":"AIM Vaccine","sponsor":"Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 mRNA Vaccine Bivalent","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AIM Vaccine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","highestDevelopmentStatusID":"1","companyTruncated":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University"},{"orgOrder":0,"company":"AIM Vaccine","sponsor":"Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 Omicron BA.5 mRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AIM Vaccine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","highestDevelopmentStatusID":"1","companyTruncated":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University"},{"orgOrder":0,"company":"AIM Vaccine","sponsor":"Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 Omicron BA.5 mRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AIM Vaccine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","highestDevelopmentStatusID":"1","companyTruncated":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University"},{"orgOrder":0,"company":"AIM Vaccine","sponsor":"The First Affiliated Hospital of Bengbu Medical University | Ningbo Rongan Biological Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"SARS-CoV-2 Omicron BA.5 mRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AIM Vaccine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AIM Vaccine \/ The First Affiliated Hospital of Bengbu Medical University | Ningbo Rongan Biological Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"AIM Vaccine \/ The First Affiliated Hospital of Bengbu Medical University | Ningbo Rongan Biological Pharmaceutical"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"S-Trimer","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clover Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Clover Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"T89","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Tianjin Tasly Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"T89","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tianjin Tasly Group \/ Tianjin Tasly Group","highestDevelopmentStatusID":"1","companyTruncated":"Tianjin Tasly Group \/ Tianjin Tasly Group"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine | Affiliated Hospital of Liaoning University of Traditional Chinese Medicine | Beijing Luhe Hospital | Qingdao Municipal Hospital | Cangzhou People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Xiyanping","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qingfeng Pharmaceutical Group \/ The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine | Affiliated Hospital of Liaoning University of Traditional Chinese Medicine | Beijing Luhe Hospital | Qingdao Municipal Hospital | Cangzhou People's Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Qingfeng Pharmaceutical Group \/ The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine | Affiliated Hospital of Liaoning University of Traditional Chinese Medicine | Beijing Luhe Hospital | Qingdao Municipal Hospital | Cangzhou People's Hospital"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"China Academy of Chinese Medical Sciences | Beijing YouAn Hospital | The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine | Beijing University of Chinese Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Xiyanping","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qingfeng Pharmaceutical Group \/ China Academy of Chinese Medical Sciences | Beijing YouAn Hospital | The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine | Beijing University of Chinese Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Qingfeng Pharmaceutical Group \/ China Academy of Chinese Medical Sciences | Beijing YouAn Hospital | The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine | Beijing University of Chinese Medicine"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Institut Pasteur Shanghai","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alphamab Oncology \/ Institut Pasteur Shanghai","highestDevelopmentStatusID":"1","companyTruncated":"Alphamab Oncology \/ Institut Pasteur Shanghai"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanyou Biopharmaceuticals \/ Shanghai Henlius Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Sanyou Biopharmaceuticals \/ Shanghai Henlius Biotech"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biologics \/ Undisclosed"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biologics \/ Vir Biotechnology"}]
Find Novel Drugs for Infections and Infectious Diseases under Development in CHINA
Details :
Amphotericin B is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Invasive Fungal Infections.
Details :
Amphotericin B is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Invasive Fungal Infections.
Details :
Peginterferon Alfa-2b is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Hepatitis B, Chronic.
Details :
Recombinant COVID-19 Vaccine is a Vaccine drug candidate, which is currently being evaluated in clinical studies for the treatment of COVID-19.
Details :
SARS-CoV-2 Omicron BA.5 mRNA Vaccine is a Vaccine drug candidate, which is currently being evaluated in clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
February 27, 2023
Lead Product(s) :
SARS-CoV-2 Omicron BA.5 mRNA Vaccine
Details :
SARS-CoV-2 Omicron BA.5 mRNA Vaccine is a Vaccine drug candidate, which is currently being evaluated in clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 22, 2022
Lead Product(s) :
SARS-CoV-2 Omicron BA.5 mRNA Vaccine
Details :
SARS-CoV-2 Omicron BA.5 mRNA Vaccine is a Vaccine drug candidate, which is currently being evaluated in clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 22, 2022
Lead Product(s) :
SARS-CoV-2 Omicron BA.5 mRNA Vaccine
Details :
COVID-19 Omicron BA.5 mRNA Vaccine is a Vaccine drug candidate, which is currently being evaluated in clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 21, 2022
Lead Product(s) :
COVID-19 Omicron BA.5 mRNA Vaccine
Reset All
